Kaku M, Kohno S, Koga H, Ishida K, Hara K
Second Department of Internal Medicine, Nagasaki University, Japan.
Chemotherapy. 1995 Mar-Apr;41(2):149-52. doi: 10.1159/000239336.
Macrolide and tetracycline antibiotics, which are protein synthesis inhibitors, are effective in the treatment of mycoplasma pneumonia. We evaluated the clinical efficacy and safety of roxithromycin, a new macrolide antibiotic, in the treatment of mycoplasma pneumonia. Roxithromycin was administered orally to patients who had been definitely diagnosed through Mycoplasma pneumoniae isolation or serum antibody titer as having mycoplasma pneumonia. The efficacy assessment was based on clinical signs and symptoms of infection as well as bacterial culture from clinical samples. Clinical efficacy was excellent in 6 cases, good in 6 cases and fair in 1 case, with an efficacy rate of 92.3%. The bacteriological effect was evaluated in 6 patients: the organism was eradicated in 4 cases and unchanged in 2 cases. In this study, the MIC of roxithromycin against M. pneumoniae fell in the range 0.0156-0.00625 mg/l. No adverse reaction was observed. As for abnormal laboratory findings, two cases showed elevated serum glutamic-pyruvic transaminase (S-GPT), one elevated serum glutamic-oxaloacetic transaminase and S-GPT, and one reduced neutrophil counts. From our results, we consider that roxithromycin is useful in the treatment of mycoplasma pneumonia.
作为蛋白质合成抑制剂的大环内酯类和四环素类抗生素对支原体肺炎的治疗有效。我们评估了新型大环内酯类抗生素罗红霉素治疗支原体肺炎的临床疗效和安全性。对通过肺炎支原体分离或血清抗体滴度确诊为支原体肺炎的患者口服罗红霉素。疗效评估基于感染的临床体征和症状以及临床样本的细菌培养。临床疗效优6例，良6例，中1例，有效率为92.3%。对6例患者评估了细菌学效果：4例病原体被清除，2例无变化。在本研究中，罗红霉素对肺炎支原体的MIC范围为0.0156 - 0.00625mg/l。未观察到不良反应。关于实验室检查异常，2例血清谷丙转氨酶（S-GPT）升高，1例血清谷草转氨酶和S-GPT升高，1例中性粒细胞计数降低。根据我们的结果，我们认为罗红霉素对支原体肺炎的治疗有用。
